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There has been growing public health concern about the high risk of HIV transmission 
posed to MSM who intentionally combine illicit drugs with sex (1).  Chemsex is the 
planned use of psychoactive drugs before or during sex to initiate, enhance or facilitate 
the sexual event (2).  The drugs associated with chemsex are crystal 
methamphetamine (crystal meth), mephedrone, gamma-hydroxybutrate/gamma-
butyrolactone (GHB/GBL), ketamine and cocaine (2, 3).  A minority of MSM engage 
in chemsex but it can involve behaviours which place this group at high risk of HIV 
acquisition (4). The behaviours at one sexual encounter (chemsex event) can include 
multiple sex partners, high rates of condomless anal intercourse (CAI), injecting of 
drugs and sharing of injecting equipment (1).       
 
A systematic review found that chemsex behaviours have a negative impact on the 
psychosocial health and well-being of 14%-25% of MSM who engage in the activity 
(1) The increased risk of poor health outcomes for this group of MSM included  
sexually transmitted infections (STIs), HIV, other blood borne viruses, mental ill health 
and isolation from social supports (1, 4). This group of men can be described as having 
experienced ‘problematic chemsex’. This is on the basis that in the substance misuse 
field, the term ‘problematic use’ is defined as when the substance has had negative-
effects on the user’s health and well-being (5).  
 
Pre-exposure prophylaxis (PrEP) is the use of antiretroviral drugs to lower the risk of 
HIV acquisition and, if used appropriately, it can reduce the risk of acquisition by over  
90% (6). The highly efficacious nature of PrEP means that this bio-medical intervention 
could substantially reduce the risk of HIV transmission for MSM that have engaged in 
chemsex. Despite this, two systematic reviews found that there was no substantive 
evidence looking at PrEP use among MSM who had experienced problematic 
chemsex (1, 7).  
 
The aim of this study was to evaluate the prevalence of PrEP use among MSM who 
had experienced problematic chemsex and to examine the biopsychosocial 
characteristics associated with PrEP use. This will help inform the development of 




We conducted a cross-sectional analysis of secondary data which was collected 
during client assessments by a United Kingdom (UK) based charity (London Friend) 
that provides a specialist substance use service.  The service is unique in offering 
specialist harm reduction information and face-to-face support to the lesbian, gay, 
bisexual and transgender (LGBT) community that are experiencing problematic 
substance use.  The service offers walk in assessments across six sites in Greater 
London. LGBT community members self-refer for an assessment and the service is 
promoted via sexual health clinics, other LGBT services and social media.  
 
The population of interest was HIV negative MSM over the age of 18 years, who had 
engaged in chemsex and self-referred to the substance use service.  A substance use 
worker completed an assessment at one interview of the men’s health and social 
needs by using a structured template (supplementary material 1). All information was 
self-reported by men at the assessment. Service users were included in the study if at 
assessment they self-reported: their gender identity as male, the same gender identity 
as at birth and their HIV status as negative.  Service users were identified as having 
engaged in chemsex if the assessment form had the following questions completed: 
1: a sexual context of drug use (question categories: clubbing, sexual, with friends, on 
my own and other); or 2: number of partners per chemsex event. Client assessment 
information collected between August 2016 to July 2018 was included in the analysis, 
with the start date corresponding to the first incorporation of information on PrEP into 
the assessment. 
The primary outcome variable for analysis was ‘ever used PrEP’. The assessment 
form had two separate questions in which men were asked if they were either currently 
using PrEP and if they had previously used PrEP. To examine the overall level of PrEP 
use, these two variables were combined to generate the outcome variable. The 
covariables in the analysis included socio-demographic characteristics, substance use 
behaviours, sexual health behaviours and mental health factors.  The assessment 
form recorded up to three substances for which clients self-reported problematic use, 
these were combined to evaluate the overall prevalence of each of the five chemsex 
drugs. There were varying incomplete levels of data for the variables of interest.    
The Mann-Whitney U-test was used for continuous variables and Fisher’s exact test 
for categorical variables to evaluate associations with PrEP use. All data that was 
missing was excluded from the analysis. Data analysis was completed using STATA 
v.15 (StataCorp, College Station, Texas, USA).  Project approval was provided in 
accordance with University College London’s ethics process. The data used for the 
analysis were anonymized and used in accordance with the relevant data protection 
legislation. 
Results 
Between August 2016 and July 2018, 165 HIV negative MSM who engaged in 
chemsex had an assessment completed.  34% (n=50/145) of the men had ever used 
PrEP.  25% (n=36/144) were currently using PrEP, and amongst the remainder (those 
who did not report current use), 13% had previously used PrEP (n=14/109).  Ten men 
that reported no current PrEP use had a missing response for previously using PrEP, 
and were assumed not to have previous use. In addition, one man reported previous 
use of PrEP without specifying whether this was also current.  Table 1 provides a 
summary of the sample’s socio-demographic characteristics in relation to PrEP use. 
There was an age range of 21 to 63 and a median age of 36 years (IQR: 30-42, n=163). 
The majority identified as gay (92%, n=152/165), were of white ethnicity (79%, 
n=130/164) and were in regular employment (65%, n=102/156).   
Substance use behaviours 
 
Fig 1 provides a summary of the use rates for problem substances according to the 
order of reporting by the participant. The most frequently reported primary problem 
substances were crystal meth (54%, n=89/164), GHB/GBL (14%, n=23/164) and 
alcohol (13%, n=21/164). In total, 85% (n=140/164) reported use of a second 
substance and 66% (n=108/164) reported a third substance.  Table 2 provides a 
summary of the overall use rates for chemsex drugs and injecting status in relation to 
PrEP use.  The three drugs (crystal meth: 74%, n=122/164, GHB/GBL: 68%, 
n=112/164, mephedrone: 42%, n=69/164) most commonly associated with chemsex 
had the highest use rates in the sample. The use of crystal meth was associated with 
a higher proportion of ‘ever using PrEP’ (40% vs 21%, p=0.047).  A similar relationship 
with crystal meth was observed for current use of PrEP, although this was not 
statistically significant (30% vs 13%, p=0.052).  One in three (35%, n=50/144) were 
currently injecting and 1 in 5 (20%, n= 29/144) had previously injected. There was no 
statistically significant association between injecting status and ever using PrEP (p= 
0.863).  
 
Sexual behaviours  
  
There was a median of 3 partners (IQR: 1-5) per chemsex event (n=136/165) and 
median of 10 sexual partners (IQR: 4-20) in the previous 3 months (n=146/165). The 
median number of recent sex partners for men who had used PrEP was 20 (IQR: 9-
25) and 10 (IQR: 4-20) for those who never used PrEP (p=0.004 for difference 
between groups). There was also a statistically significant difference between men 
who were currently (20 partners, IQR: 10-30) using PrEP and those not currently (10 
partners, IQR: 4-20) using PrEP (p=0.005). The median percentage level of condom 
use reported by men within their sex lives was 20% (IQR: 0-80%) (n=147/165). The 
median percentage of condom use for men had used PrEP was 5% (IQR: 0-50%) in 
comparison to 50% (IQR: 0-90%) for men that hadn’t used PrEP (P=0.010).  In 
addition, men currently using PrEP (5%: IQR: 0-30%) had lower levels of condom use 
compared to men who were not currently using PrEP (50%: IQR: 0-80%) (p=0.021).    
 
Mental health  
 
Table 3 provides a summary of the responses from the clients’ assessments related 
to mental health status.  One in three (n=52/165) had a current mental health diagnosis 
and 1 in 5 (n=31/144) had current contact with mental health services. One in five men 
(n=32/148) had previously self-harmed, and previous self-harm was associated with a 
lower proportion having ever used PrEP (p=0.002). The majority of the sample did not 
take psychotropic medication (69%, n=96/139).  There was no significant (p=0.620) 




To our knowledge, this is the first study to look at PrEP use among men who had 
experienced problematic chemsex. We found that 1 in 3 men had ever used PrEP, 
and these were men who had engaged in higher risk sexual behaviours than men who 
had never used PrEP.  As this population is at high risk of HIV it is encouraging that a 
substantial minority had used PrEP.    
 
Among the study sample 1 in 4 were currently using PrEP.  In comparison, a 
systematic review of MSM PrEP use reported a prevalence range of between 1%-10% 
(2001-2015), with five studies that collected data in 2015 indicating that 1 in 10 MSM 
were using PrEP (7).  However, most of studies included in the systematic review are 
from heterogenous MSM samples based in the United States of America (USA).  A 
UK based study on daily PrEP use reported that 44% of the sample had used chemsex 
related drugs prior to study enrolment (8). In addition, a study based in France on 
episodic PrEP use highlighted that 30% of the sample had been under the influence 
of psychoactive substances during sex (12).  This study also reported that the correct 
use of PrEP was associated with periods when sample members were under the 
influence of psychoactive drugs during sex (12).  
 
PrEP’s effectiveness is dependent on medication adherence, but this study could not 
examine this area as this data was not collated. A multi-site PrEP effectiveness trial 
reported that in the USA there was higher levels of adherence and congruence 
between self-reported pill taking and blood drug levels than compared to other study 
sites (Brazil, Andes, Africa/Asia) which had greater levels of disparity between self-
reported pill taking and blood drug levels (13).  A systematic review of MSM PrEP 
medication adherence in high-income countries reported generally high levels of 
adherence, but limited evidence suggested drug and alcohol use could contribute 
towards non-adherence (7). One analysis of data from a UK PrEP effectiveness trial 
reported that there was no association between self-reported adherence and chemsex 
(14). However, purposive research is required to explore the biopsychosocial factors 
which influences PrEP medication adherence among MSM chemsex participants.  
 
The limited evidence in this study suggests that there are higher levels of PrEP use 
among MSM who have experienced problematic chemsex. However, as this study 
sample self-referred to a substance use service, it may suggest they have high levels 
of awareness into their level of risk-taking behaviours. Further research is required to 
examine PrEP uptake and retention among this high-risk group.    
 
In this study, it is reassuring that there was higher level of PrEP use among men who 
had higher levels of sexual partners and lower levels of condom use than compared 
to men that had never used PrEP.  However, among the men who had never used 
PrEP, half engaged in comdomless sex and had high levels of sexual partners.  This 
indicates there is still a need to expand PrEP uptake in this high risk group. A 
systematic review of PrEP use identified that a central motivator for PrEP uptake 
among MSM was the fear of contracting HIV and this may be mediated by the men 
having multiple sex partners (7).  Two studies identified that a history of CAI or 
inconsistent condom use was associated with MSM starting on PrEP (9, 10). To 
develop and deliver more effective PrEP uptake initiatives, it would be beneficial to 
better understand the motivation for PrEP use among MSM chemsex participants.       
 
In the study’s sample crystal meth was the most commonly reported problematic 
substance and its use was associated with injecting status.  These results are 
comparable to another UK study which identified in a sample of MSM attending a 
specialist drug clinic that crystal meth was the most commonly used drug and its use 
was associated with ever injecting (11).  In addition, a systematic review on chemsex 
reported that crystal meth was specifically associated with increased risk of CAI and it 
commonly featured as a chemsex drug across different regions in high-income 
countries (1).  
 
It is important to highlight in our study that the use of crystal meth was associated with 
a higher proportion of ever using PrEP.  It could be speculated that due to the high-
risk behaviours linked with crystal meth, users have an awareness of their increased 
risk of acquiring HIV.  To more effectively deliver bespoke PrEP programmes to high-
risk chemsex participants, it would be beneficial to understand the dynamic between 
the various substances used in a sexual context and PrEP use.  PrEP has become 
increasing available in the UK, although with national disparity. Wider evidence 
suggests there are socio-economic, socio-cultural and stigma related actors that can 
act as barriers for accessing PrEP (7).  As MSM who have experienced problematic 
chemsex are at high risk of HIV acquisition, it is important we understand how this 
group can be prioritised to facilitate the expansion of PrEP uptake.  
 
Strengths and limitations  
 
To our knowledge, this is the first study to examine the biopsychosocial characteristics 
associated with PrEP use among MSM who have experienced problematic chemsex.  
However, as the study was cross sectional it was not possible to establish the direction 
of association between variables and only provides a ‘snapshot’ of the sample’s 
behaviours.  In addition, the study is limited be a small sample size and did not use 
statistical mechanisms to correct for confounding factors.    
 
Due to the limited evidence base on MSM who have experienced problematic 
chemsex, it is difficult to evaluate how representative this sample is of the wider 
problematic chemsex population.  However, this study provides insights into PrEP 
uptake among this high-risk group.  Due to the combined high-risk drug/sexual 
behaviours and potential consequences, it is fundamental we understand how PrEP 





A significant minority of MSM who have experienced problematic chemsex had used 
PrEP.  Men who had used PrEP engaged in higher risk behaviours than men who 
didn’t use PrEP, whilst those who had previously self-harmed were less likely to use 
PrEP.  Comparison with the existing literature suggests there is higher levels of PrEP 
use in this group of men than the wider MSM population.  Further research is required 
to examine the level of PrEP use, explore factors which facilitate PrEP uptake and 
evaluate whether there is an inter-relationship between chemsex and PrEP that 
influences risk behaviours, and retention and adherence to PrEP.   
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Table 1: Summary of socio-demographics 
 
Demographic Type n (%)* PrEP ever Never PrEP p-value 
     
Age categories (n=163)     
20-29 35 (22%) 9 (27%) 24 (73%) 0.296 
30-39 69 (42%) 20 (33%) 41 (67%) 
40-49 44 (27%) 14 (38%) 23 (62%) 
50-59 13 (8%) 6 (55%) 5 (45%) 
60-69 2 (1%) 1 (100%) 0 (0%) 
    
Ethnic Groups (n=164)     
Black 11 (7%) 4 (44%)  5 (56%) 0.521 
White 130 (79%) 36 (31%) 79 (69%) 
Asian 7 (4%) 4 (67%) 2 (33%) 
Mixed 8 (5%) 2 (33%) 4 (67%) 
Chinese 2 (1%) 1 (50%) 1 (50%) 
Other 6 (4%) 2 (33%) 4 (67%) 
    
Sexual Identity (n=165)     
Bisexual 6 (9%) 1 (17%) 5 (83%) 0.704 
Gay 152 (92%) 48 (35%) 89 (65%) 
Heterosexual 2 (1%) 0 (0%) 0 (0%) 
Queer 2 (1%) 1 (50%) 1 (50%) 
    
Employment Status (n=156)     
Long term sick/disabled 4 (4%) 0 (0%) 4 (100%) 0.279 
Not receiving benefits 2 (1%) 0 (0%) 1 (100%) 
Student 8 (5%) 3 (43%) 4 (57%) 
Regular employment 102 (65%) 36 (38%) 58 (62%) 
Retired 2 (1%) 1 (50%) 1 (50%) 
Unemployed 29 (19%) 5 (20%) 20 (80%) 
Unpaid voluntary work 1 (1%) 0 (0%) 1 (100%) 
Other 8 (5%) 3 (6%) 2 (2%) 
 
*% and sample number is for the overall sample. Due to non-reported data, the 























































Table 2: Chemsex drug use rates and injecting status 
 
Chemsex drug use*  Never used PrEP Have used PrEP p-value 
Crystal meth: 74%   
(n=122/164)   
 
Yes 64 (60%) 42 (40%) 0.047 




Yes 62 (61%) 39 (39%) 0.180 




Yes 40 (67%) 20 (33%) 0.860 




Yes 23 (77%) 7 (23%) 0.196 




Yes 6 (60%) 4 (40%) 0.739 
No 88 (66%) 46 (34%) 
     
Injecting status*  Never used PrEP Have used PrEP p-value 
Currently: 35% 
(n=50/144) 
 30 (68%) 14 (32%) 0.863 
Previously:20%  
(n=29/144) 
 18 (67%) 9 (33%) 
Other people inject me: 1% 
(n=1/144) 
 1 (100%) 0 (0%) 
Never: 44% 
(n=64/144) 
 35 (61%) 22 (39%) 
 
 
*% and sample number for the row variables is for the overall sample. Due to non-
reported data, the ever/never PrEP figures will not add up to this total. 
  
Table 3: Summary of mental health   
 
Mental health*  Never used PrEP Have used PrEP p-value 
Mental health diagnosis: 37%  
(n=52/142) 
Yes 36 (73%) 13 (27%) 0.130 
No 48 (59%) 33 (41%) 
Mental health services: 22%  
n=31/144 
Yes 19 (73%) 7 (27%) 0.490 
No 67 (64%) 38 (36%) 
Previous suicide attempts; 27% 
(n=42/154) 
Yes  26 (67%) 13 (33%) 1.000 
No 64 (65%) 34 (35%) 
Previous suicidal ideas; 49%  
(n=75/154) 
Yes  44 (64% 25 (36%) 0.720 
No 46 (68%) 22 (32%) 
Current self-harm: 4% 
(n=6/159)  
Yes  2 (40%) 3 (60%) 0.339 
No 90 (67%) 45 (33%) 
Previous self-harm; 22%  
(n=32/148) 
Yes  26 (90%) 3 (10%) 0.002 
No 61 (59%) 42 (41%) 
 
*% and sample number for the row variables is for the overall sample. Due to non-
reported data, the ever/never PrEP figures will not add up to this total. 
